Store launching soon — browse the catalog and join the waitlist to be notified at launch.
✦USPS Priority Mail1–3 day delivery across the U.S.Free on orders over $200
Store launching soon — browse the catalog and join the waitlist to be notified at launch.
Your cart is empty
GLP-1 / Glucagon Dual Agonist
Also known as IBI362 / LY3305677
Mazdutide is a synthetic peptide studied in research as a dual agonist of the glucagon-like peptide-1 (GLP-1) and glucagon receptors.
🚀 Launching soon — join the waitlist to be notified when this product is available.
This product is intended strictly for laboratory research use within the United States. It is not approved by the FDA for the diagnosis, treatment, cure, or prevention of any disease. Not for human or veterinary use.
By purchasing, you confirm the material will be used solely for lawful research purposes in accordance with applicable U.S. federal, state, and local regulations.
Mazdutide is a synthetic peptide studied in research as a dual agonist of the glucagon-like peptide-1 (GLP-1) and glucagon receptors.
Experimental models examine its combined incretin and glucagon signaling within controlled metabolic frameworks.
Third-party tested for purity, ID, quantity.
Mazdutide is a GLP-1/glucagon receptor dual agonist based on the oxyntomodulin scaffold, characterized in research for combined activation of two metabolic-regulatory receptors. Investigations have examined effects on glycemic control and body-weight endpoints in clinical research populations.
Studies evaluate the dual-agonist pharmacology and metabolic outcomes under structured conditions.
Mazdutide emerged from research into multi-receptor incretin agonists designed to combine the metabolic effects of GLP-1 and glucagon signaling.
Clinical trials have since characterized its efficacy and pharmacology in obesity and type 2 diabetes research.
Research into mazdutide focuses on GLP-1/glucagon dual-receptor signaling and metabolic regulation. Frameworks evaluate glycemic control, energy expenditure, and body-weight endpoints under controlled clinical and preclinical conditions.
No. Eppix Labs products are supplied exclusively for laboratory research. We do not provide dosing, administration, or usage guidance.
Each unit contains the labeled quantity of mazdutide. Independent third-party analysis verifies purity, identity, and net content per batch.
The unit contains only the research compound. Any laboratory materials required for reconstitution or experimental procedures must be sourced separately.
Duration depends entirely on research design, storage conditions, and laboratory protocol.
Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple-ascending-dose phase 1b trial
PubMedSeven glucagon-like peptide-1 receptor agonists and polyagonists for weight loss in patients with obesity or overweight: an updated systematic review and network meta-analysis of randomized controlled trials
PubMedRelated
Pentadecapeptide studied for angiogenesis signaling, tissue repair pathways, and cellular regeneration research
From$50.00
$60.00
Small molecule studied for metabolic regulation, NAD pathways, and cellular energy signaling
From$40.00
Dual peptide complex studied for actin signaling, tissue regeneration pathways, and recovery system research
From$80.00
Oral peptide format studied for systemic repair signaling and gastrointestinal pathway research
$140.00
